Disc Medicine (IRON) Retained Earnings (2020 - 2026)
Disc Medicine (IRON) posted quarterly Retained Earnings of $1.3 billion for Q2 2026, up 27.74% year-over-year from $1.0 billion in Q2 2025, and up 1.29% quarter-over-quarter from $1.3 billion in Q1 2026.
Disc Medicine (IRON) Retained Earnings (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported Retained Earnings for 7 consecutive years, with $1.3 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Retained Earnings rose 27.74% year-over-year to $1.3 billion; the TTM figure through Jun 2026 stood at $1.3 billion (up 27.74% YoY), while the FY2025 annual figure was $1.2 billion, up 68.49% from the prior year.
- Retained Earnings grew to $1.3 billion in Q2 2026 per IRON's latest filing, from $1.3 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $1.3 billion in Q2 2026 and bottomed at $288.8 million in Q4 2022.
- Historically, Retained Earnings has averaged $708.0 million across 5 years, with a median of $642.2 million in 2024.
- On a YoY basis, Retained Earnings climbed as much as 541.69% in 2022 and fell as far as 2.32% in 2022.
- Disc Medicine's Retained Earnings stood at $288.8 million in 2022, then surged by 84.81% to $533.8 million in 2023, then surged by 38.88% to $741.3 million in 2024, then soared by 68.49% to $1.2 billion in 2025, then advanced by 2.4% to $1.3 billion in 2026.
- Business Quant data shows IRON's Retained Earnings at $1.3 billion in Q2 2026, $1.3 billion in Q1 2026, and $1.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Disc Medicine | 3.02 Bn | 3.02 Bn | - | 1.28 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.28 Bn |
| Mar 31, 2026 | 1.26 Bn |
| Dec 31, 2025 | 1.25 Bn |
| Sep 30, 2025 | -449.66 Mn |
| Jun 30, 2025 | 1.00 Bn |
| Mar 31, 2025 | 991.91 Mn |
| Dec 31, 2024 | -298.00 Mn |
| Sep 30, 2024 | -268.55 Mn |
| Jun 30, 2024 | -241.90 Mn |
| Mar 31, 2024 | 553.66 Mn |
| Sep 30, 2023 | -165.07 Mn |
| Jun 30, 2023 | -150.94 Mn |
| Mar 31, 2023 | -135.00 Mn |
| Dec 31, 2022 | 288.81 Mn |
| Sep 30, 2022 | 314.85 Mn |
| Jun 30, 2022 | -207.01 Mn |
| Mar 31, 2022 | -199.92 Mn |
| Dec 31, 2021 | -65.39 Mn |
| Sep 30, 2021 | -166.87 Mn |
| Jun 30, 2021 | 305.99 Mn |